PARKE-DAVIS EXPANDING OTC DIPHENHYDRAMINE HCI FRANCHISE WITH BENADRYL antihistamine products, the firm announced in a May 21 release. Parke-Davis (P-D), which currently markets diphenhydramine OTC in the antitussive Benylin, said it will introduce its three OTC Benadryl formulations by the end of May. The three formulations are Benadryl 25 (25 mg caps), Benadryl Elixir for children, and Benadryl Decongestant capsules, which contain 25 mg diphenhydramine HCl and 60 mg pseudoephedrine, the firm said. The elixir contains 12.5% diphenhydramine. With the introduction of the new Benadryl products, P-D will apparently be the first firm to take advantage of the OTC availability of diphenhydramine HCl as an antihistamine. In the Antihistamine Tentative Final Monograph, published in January, FDA said it would allow OTC indications for the ingredient. In permitting the ingredient for OTC antihistamine use the agency said that products must carry a label statement: "May cause marked drowsiness" ("The Pink Sheet" Jan. 21, p. 13). P-D's effort to break into the OTC antihistamine market with Benadryl comes two weeks after approval of Merrell Dow's non-sedating Rx antihistamine Seldane. In letters to MDs announcing the OTC products, P-D VP Marketing C. J. Cowles asserted the company will maintain a strong commitment to the Rx product. The company "will continue its strong ethical promotion of Benadryl on Rx to physicians through Journal advertising, detailing, sampling, direct mail, and at conventions," Cowles said. "At the same time physician recommendations for Benadryl OTC will be encouraged." He pointed out to the MDs that "for all indications other than hay fever, other upper respiratory allergies and the common cold, Benadryl remains available only on your Rx." The whsle. prices for the Benadryl products are: $2.07 for a box of 24 of the 25 mg capsules; $2.58 for a box of 24 of the decongestant capsules; and $2.27 for a 4 oz. bottle of the elixir, the firm said. The OTC launch will be supported by print ads and natl. television commericals.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
FDA Commissioner Martin Makary suggested 60 new molecular entities could be approved in 2025, which appears possible, but can the strained staff deliver?
PharmaMar has voluntarily withdrawn its marketing authorization application for Aplidin to treat multiple myeloma in the EU – almost a decade after it first filed the drug for EU approval and following years of court proceedings.
Antibiotics that tackle antimicrobial resistance are to be automatically included in Italy’s Innovative Medicines Fund, which is designed to provide quick access to innovative medicines.
